A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of LY2216684 on heart rate and blood
pressure in research participants with MDD who are being treated with an SSRI (selective
serotonin reuptake inhibitors). Information about any side effects that may occur will also
be collected. The duration of participation in this study is approximately 24 days not
including the screening visit. This study requires 1 clinic confinement of 17 days/16 nights
and 1 Follow-up Outpatient Visit. A screening visit is required within 30 days prior to the
start of the study. In both periods 1 and 2, the study involves 4 single daily doses of 18 mg
LY2216684 or placebo taken as 2 tablets by mouth. In period 3, the study involves four single
daily doses of 36 mg LY2216684 or placebo taken as 4 tablets by mouth.